Calibr-Ì: Comparative Evaluation of Phantomless Calibration Methods to Quantify Bone Mineral Density for Opportunistic Analysis of CT Scans
Launched by ISTITUTO ORTOPEDICO RIZZOLI · Jun 6, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called Calibr-Ì, is studying new ways to measure bone mineral density (BMD) using CT scans to help diagnose osteoporosis more effectively. Osteoporosis is a condition that weakens bones, making them more likely to break. Traditionally, doctors use a specific test called DXA to measure BMD, but there are some limitations with this method. This trial aims to see if using CT scans, which are commonly performed for other reasons, can provide a better assessment of bone health without needing a separate appointment for a DXA test.
To be eligible for the trial, participants must be 18 years or older, of any gender or ethnicity, and have a reason to undergo a CT scan of their lower back or abdomen, where the spine and surrounding areas can be clearly seen. However, individuals with certain conditions, like severe spine issues or those who are pregnant, cannot participate. If you join the study, you can expect to have your CT scan analyzed to determine your bone density, which could lead to better ways to manage or prevent osteoporosis in the future. This research is important as it may help improve the diagnosis and treatment of a condition that affects many people, particularly older adults.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Both sexes.
- • All ethnicities.
- • Age equal or above 18 years.
- • Any clinical indication (no specific pathology is required) for a CT scan of the lumbosacral spine or abdomen in which the entire lumbar spine (L1 to L5), paravertebral muscles, abdominal aorta, and subcutaneous adipose tissue are visible.
- • Ability to give informed consent.
- Exclusion Criteria:
- • General contraindications to CT examination, including pregnancy or body weight/size exceeding scanner limits.
- • Severe degenerative manifestations of the lumbosacral spine.
- • Severe scoliosis of the lumbosacral spine.
- • Surgical hardware that prevents adequate CT scanning.
- • Oncologic pathology in progress or in recent history.
- • Any other situation deemed incompatible with the study by the designated physician or investigator.
About Istituto Ortopedico Rizzoli
Istituto Ortopedico Rizzoli is a renowned orthopedic research and treatment institute based in Bologna, Italy, dedicated to advancing musculoskeletal health through innovative clinical trials and cutting-edge medical practices. With a strong emphasis on research, the institute collaborates with leading experts in orthopedics, rehabilitation, and related fields to develop and evaluate new therapies and surgical techniques. Committed to improving patient outcomes, Istituto Ortopedico Rizzoli not only focuses on high-quality clinical care but also fosters a robust research environment that supports the translation of scientific findings into clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, Bo, Italy
Auckland, , New Zealand
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported